The impact of APOE status on relationship of biomarkers of vascular risk and systemic inflammation to neuropsychiatric symptoms in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 40, Issue 4, 2014, Pages 887-896

  Hall, James R ^a,b   Wiechmann, April R ^a,b   Johnson, Leigh A ^a,b   Edwards, Melissa ^c   Barber, Robert C ^a   Cunningham, Rebecca ^a   Singh, Meharvan ^a   O'Bryant, Sid E ^a,b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b University of North Texas Health Science Center   (United States)

^c UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Alzheimer's disease; APOE; gender; neuropsychiatric symptoms

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; HOMOCYSTEINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 7; INTERLEUKIN 8; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; APATHY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HETEROZYGOTE; HUMAN; HYPERACTIVITY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; NEUROPSYCHIATRIC INVENTORY; NEUROPSYCHIATRIC SYMPTOM; NEUROPSYCHIATRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SEX DIFFERENCE; SYSTEMIC DISEASE; SYSTEMIC INFLAMMATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPLICATION; DEFENSE MECHANISM; GENETICS; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; CHOLESTEROL; CYTOKINES; FEMALE; HOMOCYSTEINE; HUMANS; INFLAMMATION; MALE; PSYCHIATRIC STATUS RATING SCALES; REGRESSION (PSYCHOLOGY); SEX FACTORS; TRIGLYCERIDES;

EID: 84901780800     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131724     Document Type: Article

References (54)

1. Assal F, Cummings JL (2002) Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 15, 445-450.
2. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 288, 1475-1483.
3. Beaudreau SA, Spira AP, Gray HL, Depp CA, Long J, Rothkopf M, Gallagher-Thompson D (2008) The relationship between objectively measured sleep disturbance and dementia family caregiver distress and burden. J Geriatr Psychiatry Neurol 21, 159-165.
4. Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, D'Onofrio G, Seripa D, Sancarlo D, Pilotto A, Solfrizzi V (2010) Metabolic syndrome and cognitive impairment: Current epidemiology and possible underlying mechanisms. J Alzheimers Dis 21, 691-724.
5. Allegri RF, Sarasola D, Serrano CM, Taragano FE, Arizaga RL, Butman J, Loñ L (2006) Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer's disease. Neuropsychiatr Dis Treat 2, 105-110.
6. Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C (2010) Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 22, 346-372.
7. Okura T, Langa KM (2011) Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: The Aging, Demographics, and Memory Study (ADAMS). Alzheimer Dis Assoc Disord 25, 116-121.
8. Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS (2011) Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement 7, 532-539.
9. Seripa D, Panza F, Franceschi M, D'Onofrio G, Solfrizzi V, Dallapiccola B, Pilotto A (2009) Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. Ageing Res Rev 8, 214-236.
10. Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW (1999) Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. Biol Psychiatry 45, 422-425.
11. Cummings JL, Mega M, Gray K (1994) The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
12. Pritchard AL, Harris J, Pritchard CW, Coates J, Haque S, Holder R, Bentham P, Lendon CL (2007) The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease. J Neurol Neurosurg Psychiatry 78, 123-126.
13. Delano-Wood L, Houston WS, Emond JA, Marchant NL, Salmon DP, Thal LJ, Jeste DV, Bondi MW (2008) APOE genotype predicts depression in women with Alzheimer's disease. Int J Geriatr Psychiatry 23, 632-636.
14. D'Onofrio G, Sancarlo D, Panza F, Copetti M, Cascavilla L, Paris F, Seripa D, Matera MG, Solfrizzi V, Pellegrini F, Pilotto A (2012) Neuropsychiatric symptoms and functional status in Alzheimer's disease and vascular dementia patients. Curr Alzheimer Res 9, 759-771.
15. Fritze F, Ehrt U, Sønnesyn H, Kurz M, Hortobágyi T, Nore SP, Ballard C, Aarsland D (2011) Depression in mild dementia: Associations with diagnosis, APOE genotype and clinical features. Int J Geriatr Psychiatry 26, 1054-1061.
16. Muller-Thomsen T, Arlt S, Ganzer S, Mann U, Mass R, Naber D, Beisiegel U (2002) Depression in Alzheimer's disease might be associated with apolipoprotein E e4 allele frequency in women but not in men. Dement Geriatr Cogn Disord 14, 59-63.
17. Robertson J, Curley J, Kaye J, Quinn J, Pfankuch T, Raber J (2005) apoE isoforms and measures of anxiety in probable AD patients and Apoe-/- mice. Neurobiol Aging 26, 637-643.
18. Michels A, Multhammer M, Zintl M, Mendoza MC, Klünemann HH (2012) Association of apolipoprotein E å4 (ApoE å4) homozygosity with psychiatric behavioral symptoms. J Alzheimers Dis 28, 25-32.
19. Monastero R, Mariani E, Camarda C, Ingegni T, Averna MR, Senin U, Camarda R, Mecocci P (2006) Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease. Acta Psychiatr Scand 113, 59-63.
20. Chang JB, Wang PN, ChenWT, LiuCY, Hong CJ, Lin KN, Liu TY, ChiCW, LiuHC(2004)ApoEepsilon4 allele is associated with incidental hallucinations and delusions in patients with AD. Neurology 63, 1105-1107.
21. Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Caltagirone C (2006) Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer's disease with late onset. Eur J Neurol 13, 176-182.
22. Van der Flier WM, Staekenborg S, Pijnenburg YA, Gillissen F, Romkes R, Kok A, Bouwman FH, Scheltens P (2007) Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord 23, 42-46.
23. Zdanys KF, Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, Garman KS, Tampi RR, Gelernter J, van Dyck CH (2007) Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. Neuropsychopharmacology 32, 171-179.
24. Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP (2004) Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75, 1327-1330.
25. Lopez OL, Kamboh MI, Becker JT, Kaufer DI, DeKosky ST (1997) The apolipoprotein E epsilon 4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology 49, 794-797.
26. Lyketsos CG, Baker L, Warren A, Steele C, Brandt J, Steinberg M, Kopunek S, Baker A (1997) Depression, delusions, and hallucinations in Alzheimer's disease: No relationship to apolipoprotein E genotype. J Neuropsychiatry Clin Neurosci 9, 64-67.
27. Hirono N, Mori E, Yasuda M, Imamura T, Shimomura T, Hashimoto M, Tanimukai S, Kazui H, Yamashita H (1999) Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 11, 66-70.
28. Liu CY, Hong CJ, Liu TY, Lin KN, Wang PN, Chi CW, Chuang YY, Liu HC (2002) Lack of association between the apolipoprotein E genotype and depression in Alzheimer's disease. J Geriatr Psychiatry Neurol 15, 20-23.
29. Hollingworth P, Hamshere ML, Moskvina V, Dowzell K, Moore PJ, Foy C, Archer N, Lynch A, Lovestone S, Brayne C, Rubinsztein DC, Lawlor B, Gill M, Owen MJ, Williams J (2006) Four components describe behavioral symptoms in 1, 120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc 54, 1348-1354.
30. Borroni B, Costanzi C, Padovani A (2010) Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Curr Alzheimer Res 7, 158-164.
31. Craig D, Hart DJ, McIlroy SP, Passmore AP (2005) Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 19, 154-157.
32. Panza F, Frisardi V, Seripa D, D'Onofrio G, Santamato A, Masullo C, Logroscino G, Solfrizzi V, Pilotto A (2012) Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. Ageing Res Rev 11, 87-103.
33. Panza F, Seripa D, D'Onofrio G, Frisardi V, Solfrizzi V, Mecocci P, Pilotto A (2011) Neuropsychiatric symptoms, endophenotypes, and syndromes in late-onset Alzheimer's Disease: Focus on APOE gene. Int J Alzheimers Dis 2011, 721457.
34. Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, D'Onofrio G, Seripa D, Sancarlo D, Pilotto A, Solfrizzi V (2010) Metabolic syndrome and cognitive impairment: Current epidemiology and possible underlying mechanisms. J Alzheimers Dis 21, 691-724.
35. Hall JR, Johnson L, Barber R, Vo H, Winter S, O'Bryant S (2012) Biomarkers of basic activities of daily living in mild Alzheimer's disease. J Alzheimers Dis 31, 429-437.
36. Hall JR, Wiechmann AW, Johnson LA, Edwards ML, Barber RC, Winter AS, Singh M, O'Bryant SE (2013) Bbiomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer's disease. J Alzheimers Dis 35, 363-371.
37. Xing Y, Qin W, Li F, Jia XF, Jia J (2012) Apolipoprotein E å4 status modifies the effects of sex hormones on neuropsychiatric symptoms of Alzheimer's disease. Dement Geriatr Cogn Disord 33, 35-42.
38. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939-944.
39. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12, 233-239.
40. Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Girtler N, Holmes C, Hurt C, Marriott A, Mecocci P, Nobili F, Ousset PJ, Reynish E, Salmon E, Tsolaki M, Vellas B, Robert PH (2007) Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: Part I. Dement Geriatr Cogn Disord 24, 457-463.
41. Damoiseaux JS, SeeleyWW, Zhou J, Shirer WR, Coppola G, Karydas A, Rosen HJ, Miller BL, Kramer JH, Greicius MD; Alzheimer's Disease Neuroimaging Initiative (2012) Gender modulates theAPOEå4 effect in healthy older adults: Convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci 32, 8254-8262.
42. Wu X, Hsuchou H, Kastin AJ, HeY, Khan RS, Stone KP, Cash MS, Pan W (2011) Interleukin-15 affects serotonin system and exerts antidepressive effects through IL15R receptor. Psychoneuroendocrinology 36, 266-278.
43. Pan W, Wu X, He Y, Hsuchou H, Huang EY, Mishra PK, Kastin AJ (2013) Brain interleukin-15 in neuroinflammation and behavior. Neurosci Biobehav Rev 37, 184-192.
44. MarlattMW, Lucassen PJ, Perry G, Smith MA, Zhu X (2008) Alzheimer's disease: Cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis 15, 199-210.
45. Bossù P, Ciaramella A, Salani F, Bizzoni F, Varsi E, Di Iulio F, Giubilei F, GianniW, Trequattrini A, Moro ML, Bernardini S, Caltagirone C, Spalletta G (2008) Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment. Brain Behav Immun 22, 487-492.
46. Ojala J, Alafuzoff I, Herukka SK, van Groen T, Tanila H, Pirttilä T (2009) Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol Aging 30, 198-209.
47. Adibhatla RM, Hatcher JF (2008) Altered lipid metabolism in brain injury and disorders. Subcell Biochem 49, 241-268.
48. Gamba P, Testa G, Sottero B, Gargiulo S, Poli G, Leonarduzzi G(2012) The link between altered cholesterol metabolism and Alzheimer's disease. Ann N Y Acad Sci 1259, 54-64.
49. Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, Thome J, DarieCC(2012) Potential biomarkers in psychiatry: Focus on the cholesterol system. J Cell Mol Med 16, 1184-1195.
50. Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JC (2010) Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res 49, 159-170.
51. Shalev H, Serlin Y, Friedman A (2009) Breaching the bloodbrain barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol 2009, 278531.
52. Orellana DI, Quintanilla RA, Maccioni RB (2007) Neuroprotective effect of TNF alpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase. Biochim Biophys Acta 1773, 254-263.
53. O'Bryant SE, Hobson VL, Hall JR, Barber RC, Zhang S, Johnson L, Diaz-Arrastia R, Texas Alzheimer's Research, Consortium (2011) Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement Geriatr Cogn Disord 31, 31-36.
54. Chow TW, Fridhandler JD, Binns MA, Lee A, Merrilees J, Rosen HJ, Ketelle R, Miller BL (2012) Trajectories of behavioral disturbance in dementia. J Alzheimers Dis 31, 143-149.